NCT03729245 2023-04-11A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)Nektar TherapeuticsPhase 3 Terminated623 enrolled 14 charts
NCT04969861 2023-01-12BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)Nektar TherapeuticsPhase 2/3 Terminated1 enrolled 6 charts
NCT04052204 2021-10-14Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid TumorsPfizerPhase 1/2 Terminated3 enrolled 12 charts